Abstract
Type 1 diabetes (T1D) is one of the focuses of scientific research worldwide. Particularities such as its incidence in the younger population, its multifactorial character and the possibility of giving these patients a quality of life and an average life expectancy equal to that of a healthy individual have led to a great investment in research in this area. Since the therapeutic approach of this disease is based on the use of insulin, the progress in the development of new molecules is remarkable. Currently available are new insulins of ultra-fast and ultra-prolonged action, which have revolutionized the treatment of T1D, namely by allowing the mimicking of physiological insulin secretion and thus increasing the effectiveness and safety of therapy. These new insulins have administration and action profiles more adapted and flexible to the diabetic’s day-to-day life, which allows for the optimization of the therapeutic outcome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
